EP Patent

EP3996713B1 — Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate

Assigned to Eli Lilly and Co · Expires 2024-12-04 · 1y expired

What this patent protects

Patent listed against lasmiditan-succinate.

Drugs covered by this patent

lasmiditan-succinate (LASMIDITAN SUCCINATE)

Patent Metadata

Patent number: EP3996713B1
Jurisdiction: EP
Classification: —
Expires: 2024-12-04
Drug substance claim: No
Drug product claim: No
Assignee: Eli Lilly and Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.